Gossamer Bio prices upsized IPO at $16

Shutterstock photo

Gossamer Bio, which is developing in-licensed immunotherapies for asthma and other indications, raised $276 million by offering an upsized 17.3 million shares at $16, the indicated IPO price. Insiders indicated an interest in purchasing $100 million (36% of deal size) worth of shares on the IPO. At pricing, Gossamer commands a fully diluted market cap of $1.1 billion. Gossamer Bio plans to list on the Nasdaq under the symbol GOSS. BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as lead managers on the deal.

The article Gossamer Bio prices upsized IPO at $16 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?